Semax

Semax is a synthetic peptide, specifically a heptapeptide (a chain of seven amino acids: Met-Glu-His-Phe-Pro-Gly-Pro). It is a synthetic analog of a fragment of the adrenocorticotropic hormone (ACTH), designed to mimic its cognitive-enhancing (nootropic) and neuroprotective properties without having its hormonal effects.

Key Benefits

May support cognitive function, focus, and mental clarity
Commonly researched for neuroprotection and supporting brain recovery under stress
May help enhance memory formation and learning capacity
Research suggests potential benefits for mood regulation and stress resilience

Order Now

FDA-Approved Uses

Semax has no FDA-approved indication. It is an approved prescription drug in Russia and some Eastern European countries.

Regulatory status (as of May 2026):

Previously: FDA Category 2
April 22, 2026: Removed from Category 2 following HHS Secretary directive
Standard 503A/503B pharmacy regulations now apply.
PCAC review scheduled July 24, 2026 at FDA White Oak Campus
Specific indications under review: Cerebral ischemia, migraine, trigeminal neuralgia

Russian-approved indications (not valid in USA):

Acute ischemic stroke and recovery
Optic nerve diseases / glaucomatous optic neuropathy
Cognitive impairment
Attention deficit
Peptic ulcer disease (gastrointestinal protection)

Conditions studied in research (off-label worldwide):

Nootropic / cognitive enhancement (focus, memory, learning)
Anxiety and stress management (lower doses)
ADHD (proposed in literature)
Neuroprotection after TBI or ischemia
Depression (limited data)
Rett syndrome (proposed)

Trade Names in USA and Manufacturers

Russian pharmaceutical brands (prescription, not available in US pharmacies):

Semax 0.1% nasal drops — originally developed by Institute of Molecular Genetics (IMG), Russian Academy of Sciences, Moscow
N-Acetyl Semax: acetylated form with enhanced BBB penetration and extended activity
N-Acetyl Semax Amidate (NASA): further modified version with longest duration of action

US availability:

As of April 22, 2026: Technically available via licensed 503A compounding pharmacies with valid physician prescription (Category 2 removal). Formal FDA rulemaking pending — verify current legal status before dispensing.
Grey-market online vendors (unregulated): Available but not FDA-verified
Russian pharmaceutical products: Imported through informal channels; not FDA-inspected

Dosage

No FDA-approved US dosing protocol. The following reflects Russian clinical practice and off-label use.

Intranasal spray (most common route):

Standard clinical dose: 300–600 mcg/day
(0.1% solution: 1–2 drops per nostril, 1–3x daily)
Nootropic/cognitive use: 200–300 mcg/day
Neuroprotective use: 600–900 mcg/day (clinical setting)

Subcutaneous injection (off-label):

Typical dose: 50–300 mcg once daily in the morning
Range: 100–600 mcg/day depending on indication

Cycling protocols:

Typical cycle: 10–14 days of daily use, then 2–4 week break
Some users run 5 days on / 2 days off
Reason for cycling: Prevent tolerance development

Availability forms:

Nasal spray (0.1% solution): Preferred for CNS effects due to direct nasal-brain pathway
Lyophilized powder for reconstitution (injectable)
Transdermal forms: Available but less studied

Pricing

Russian pharmaceutical nasal drops (imported):
~$30–$60 per bottle (0.1% solution, 3 mL)
Monthly cost: ~$30–$80/month depending on dose

Compounded Semax (503A pharmacy, where currently legal with prescription):
~$80–$200/month depending on pharmacy, formulation, and dose

Research peptide vendors (unregulated):
~$30–$70/vial or bottle

N-Acetyl Semax / NASA variants:
Typically 20–50% more expensive than standard Semax

Coverage by Insurance Type

Not covered by any insurance:
– ACA Marketplace: Not covered ❌
– Employer Insurance: Not covered ❌
– Medicare Part D: Not covered ❌
– Medicaid: Not covered ❌
– TRICARE: Not covered ❌

All access is cash-pay only. No insurance pathway exists for unapproved compounds.
If PCAC review (July 2026) leads to Category 1 classification, 503A compounding will be legally available with prescription — but insurance coverage for compounded peptides remains rare.

Tips

Monitor the July 24, 2026 PCAC review outcome — FDA will evaluate Semax specifically for cerebral ischemia, migraine, and trigeminal neuralgia. A favorable outcome enables licensed 503A pharmacy access.
If you are using imported Russian nasal drops: quality and potency can vary between batches. Compounded pharmaceutical-grade product from a licensed 503A pharmacy (where available) is preferable.
Semax upregulates BDNF — the same neurotrophin targeted by many antidepressants and cognitive therapies.
Short cycle protocols (10–14 days on, break) are consistently recommended in Russian clinical practice to maintain sensitivity and avoid tolerance.
Administer in the morning if used for cognitive/focus effects; the stimulating nature may disrupt sleep if taken late in the day.

Side Effects

From Russian clinical literature and off-label reporting (limited independent Western studies):

Mild and commonly reported:
– Nasal irritation / discoloration of nasal cavity with intranasal use (~10% in Russian data)
– Mild headache (transient; usually first few days)
– Transient dizziness
– Mild stimulant effect: Increased alertness, energy — may cause difficulty sleeping if taken late
– Increased anxiety: Reported by some users, especially at higher doses or in individuals with baseline anxiety

Less common:
– Elevated blood glucose in patients with diabetes: Noted in Russian clinical data
– Irritability or mood changes at higher doses
– Nasal dryness or epistaxis (nosebleed) with intranasal use

Animal study signals:
– Pro-oxidant effects at high doses in some animal models — significance for humans at clinical doses unclear

Overall safety profile:
– Russian clinical data spanning decades reports low toxicity and no significant hormonal effects
– No known dependence, addiction, or withdrawal syndrome
– Two key published concerns: nasal discoloration (~10%) and elevated blood glucose in diabetics

⚠️ Independent Western long-term safety data is very limited. Safety profile relies heavily on Russian clinical experience.

Contraindications

No formal FDA contraindications (no approved US label).

Based on Russian prescribing information and pharmacological properties:
– Known hypersensitivity to Semax or its components
– Pregnancy and breastfeeding: Insufficient safety data; not recommended
– Children: Limited data; not established as safe in pediatric population
– Psychosis or acute psychiatric conditions: Dopaminergic/serotonergic modulation may worsen symptoms; use with caution
– Active seizure disorder: Theoretical concern; use with caution
– Diabetes mellitus: Elevated blood glucose reported — monitor blood sugar carefully
– Combined use with MAOIs or strong serotonergic drugs: Theoretical interaction via serotonin pathway modulation; caution advised

Pharmacology

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide (7 amino acids) derived from the adrenocorticotropic hormone fragment ACTH(4-10). It was developed at the Institute of Molecular Genetics, Russian Academy of Sciences. The additional Pro-Gly-Pro sequence at the C-terminus was added to increase resistance to enzymatic degradation and extend biological activity compared to the native ACTH(4-10) fragment. MW approximately 887 Daltons. The peptide does not have ACTH-like hormonal activity (does not stimulate cortisol or adrenal function) — the parent ACTH(4-10) sequence retains CNS-active properties without the endocrine activity of full ACTH. Available as: 0.1% nasal spray solution (intranasal route exploits the nasal-olfactory pathway for direct CNS delivery without full systemic absorption), lyophilized powder for injection, and compounded formulations.

Mechanism of action

Semax exerts its primary effects through multiple neurotrophin and neurotransmitter pathways:

1. BDNF Upregulation (primary/most documented mechanism):
Semax stimulates expression and release of BDNF (brain-derived neurotrophic factor) in the hippocampus and cortex. BDNF promotes neurogenesis, synaptic plasticity, and neural circuit repair. This is considered the key mechanism underlying cognitive enhancement and neuroprotective effects.

2. Serotonin system modulation:
Semax increases serotonin metabolism in striatum and hippocampus — contributing to mood, anxiety reduction (low dose), and cognitive effects.

3. Dopamine system modulation:
Modulates dopaminergic activity in limbic regions — contributing to motivation, attention, and reward processing.

4. Enkephalinase inhibition:
Inhibits enzymes that break down endogenous enkephalins (opioid peptides) — prolonging their activity, which may contribute to analgesic and anxiolytic effects.

5. Neuroprotection:
In ischemia/stroke models, reduces oxidative stress, decreases neuronal death, and promotes recovery — supported by Russian clinical stroke data.

6. NO (nitric oxide) modulation:
Protective effects on cardiac tissue in animal myocardial infarction studies may be mediated through NO pathways.

Result Claims By Different Companies

Russian Institute of Molecular Genetics / Russian pharmaceutical clinical data:

Stroke recovery (Russian clinical trials):
– Reduced neurological deficit and improved functional outcomes when administered within 6 hours of ischemic stroke onset
– Improved cognitive recovery post-stroke compared to standard care controls in Russian hospital-based trials

Glaucoma / optic nerve disease:
– Kurysheva et al.: Semax administration stabilized or improved visual field parameters in patients with optic nerve disease and glaucoma

Cognitive and ADHD (Russian literature):
– Improvements in attention, memory consolidation, and learning speed reported in Russian studies
– Tsai (2007) proposed Semax as a candidate therapeutic for ADHD and Rett syndrome based on its BDNF-upregulating mechanism

ADDF (Alzheimer’s Drug Discovery Foundation) Cognitive Vitality Report:
– Noted ‘very little human evidence for potential side effects’ from published data
– Noted favorable low-toxicity profile based on Russian clinical experience
– Concluded evidence insufficient to recommend for cognitive use in Western clinical practice without further RCT data

⚠️ The majority of clinical evidence originates from Russian institutions. Independent Western clinical trials are very limited. No Phase 3 data reviewed by the FDA exists for any indication.

Disclaimer

This content about “Semax” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.